CD532 is an inhibitor of Aurora A kinase activity (IC₅₀= 48 nM) and the protein-protein interaction between N-Myc and Aurora A kinase.¹It also inhibits several cyclin-dependent kinases (CDKs), FGFRs, MEKs, and PDGFRs, as well as FLT3, KIT, and RET at 10 µM.²CD532 induces degradation of N-Myc in SK-N-BE(2) neuroblastoma cells (EC₅₀= 223 nM).¹It prevents S-phase entry in SK-N-BE(2) cells when used at a concentration of 1 µM.¹CD532 (25 mg/kg) reduces tumor growth and increases survival in aMYCN-amplified SMS-KCN neuroblastoma mouse xenograft model.

1.Gustafson, W.C., Meyerowitz, J.G., Nekritz, E.A., et al.Drugging MYCN through an allosteric transition in Aurora kinase ACancer Cell26(3)414-427(2014) 2.Lee, J.K., Phillips, J.W., Smith, B.A., et al.N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cellsCancer Cell29(4)536-547(2016)